Print page |
Email page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
PETALUMA, Calif. (November 1, 2007) - Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) announced today that the company will be presenting at the SMH Capital Markets Investor Growth Conference to be held November 8-9, 2007 at the New York Palace Hotel. The company's chairman and CEO, Hoji Alimi, is scheduled to present an overview of the company and its clinical program on Thursday, November 8, 2007 at 8:30 a.m. (ET). For more information on this event please visit: http://www.smhib.com.
About Oculus
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated significant wound healing in chronic and acute wounds. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is www.oculusis.com.
Oculus Innovative Sciences, Inc.
Dan McFadden
Director of Public and Investor Relations
(425) 753-2105
dmcfadden@oculusis.com
The Ruth Group
Sara Ephraim (Investors)
(646) 536-7002
sephraim@theruthgroup.com
Jason Rando / Janine McCargo (Media)
(646) 536-7025 / 7033
jrando@theruthgroup.com
jmccargo@theruthgroup.com